Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

734
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
734
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controlling Photophysical Properties in Bis-Cyclometalated Ir(III)-Terpyridine Complexes through Photoinduced Intraligand Charge Transfer.

Inorganic chemistry·2026
Same author

The significance of the ketolytic gene OXCT1 in metabolism, intracellular signaling and disease development.

Cellular and molecular life sciences : CMLS·2026
Same author

An Alginate Hydrogel-Lipid Nanodispersion Bio-Mask: A Preliminary Study of Skin Hydration, Barrier Function, and Regenerative Potential.

Materials (Basel, Switzerland)·2026
Same author

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma.

Molecular oncology·2026
Same author

Spectroscopic and Theoretical Analysis of <i>N</i>-Ethylphenothiazine Derivatives: Alkyl Chain Length Effects on Solvatochromism, Fluorescence Efficiency, and Excited-State Polarity.

The journal of physical chemistry. B·2026
Same author

Integrated <i>In Vitro</i> and <i>In Silico</i> Profiling of Piperazinyl Thiosemicarbazone Derivatives Against <i>Trypanosoma cruzi</i>: Stage-Specific Activity and Enzyme Inhibition.

Pharmaceuticals (Basel, Switzerland)·2026

Related Experiment Video

Updated: Feb 19, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives
11:51

Facile Preparation of 4-Substituted Quinazoline Derivatives

Published on: February 15, 2016

12.4K

Styrylquinoline Derivatives as IGF1R Inhibitors.

Patryk Zioła1, Katarzyna Malarz1, Marcin Pacholczyk2

  • 1A. Chełkowski Institute of Physics, University of Silesia in Katowice, 75 Pułku Piechoty 1a, 41-500 Chorzów, Poland.

ACS Medicinal Chemistry Letters
|February 18, 2026
PubMed
Summary

Styrylquinoline analogues show antiproliferative effects against glioblastoma. These compounds are potent inhibitors of insulin-like growth factor 1 receptor tyrosine kinase, indicating therapeutic potential.

Keywords:
IGF1R inhibitorsantiproliferative activityglioblastoma multiformestyrylquinoline

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.6K

Related Experiment Videos

Last Updated: Feb 19, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives
11:51

Facile Preparation of 4-Substituted Quinazoline Derivatives

Published on: February 15, 2016

12.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.6K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Glioblastoma multiforme is an aggressive brain tumor with limited treatment options.
  • Tyrosine kinase signaling pathways are crucial in glioblastoma progression.
  • Styrylquinoline derivatives have demonstrated antiproliferative activity.

Purpose of the Study:

  • To investigate the tyrosine kinase inhibitory potential of styrylquinoline analogues.
  • To establish structure-activity relationships for antiproliferative effects against glioblastoma.
  • To identify specific receptor tyrosine kinase targets for these compounds.

Main Methods:

  • Synthesis and screening of styrylquinoline analogues for antiproliferative activity.
  • Structure-activity relationship analysis based on substituent effects (OH, NO2, F, OAc).
  • Screening against a panel of receptor tyrosine kinases and molecular docking simulations.

Main Results:

  • Styrylquinoline derivatives exhibit significant antiproliferative activity against glioblastoma.
  • Hydroxyl (OH) and nitro (NO2) substituents enhanced activity, while fluorine (F) and acetate (OAc) reduced it.
  • Compounds showed high potential as insulin-like growth factor 1 receptor (IGF-1R) inhibitors, supported by molecular docking studies.

Conclusions:

  • Styrylquinoline derivatives are promising candidates for glioblastoma treatment.
  • Targeting the insulin-like growth factor 1 receptor (IGF-1R) pathway with these analogues offers a potential therapeutic strategy.
  • Further development of these compounds could lead to novel glioblastoma therapies.